Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors
October 10 2018 - 7:30AM
Data to be Presented at Neuro-Oncology Annual
Scientific Meeting
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced that new data
relating to its molecule WP1122 will be presented at the upcoming
Society for Neuro-Oncology Annual Scientific Meeting.
“We continue to make progress in the development of our
inhibitor of glycolysis, WP1122,” commented Dr. Donald Picker,
Moleculin’s Chief Science Officer. “We believe that we have
discovered new data during our IND-enabling research with animals
that confirms a highly beneficial metabolism of WP1122 and
significant organ accumulation of the inhibitor of glycolysis in
the brain and also in the pancreas. This is especially
significant because both brain and pancreatic tumors are highly
dependent upon glucose for survival and WP1122 appears to have the
ability to inhibit glycolysis, the process by which these tumors
convert glucose into energy.”
Walter Klemp, Moleculin’s Chairman and CEO added, “Metabolic
inhibition of tumors is conceptually a very important approach, and
we believe we have a clear translational focus. We have been
pushing hard to prepare WP1122 for Investigational New Drug (IND)
status. It is encouraging to have discoveries during this
process that appear to confirm the initial premise and give us more
hope that WP1122 could become an important new way to deal with
difficult cancers like glioblastoma and pancreatic cancer.”
The Society for Neuro-Oncology is a multidisciplinary
organization dedicated to promoting advances in neuro-oncology
through research and education. Now in its twenty fourth
year, the Society continues to grow and mature as the premier North
American organization for clinicians, basic scientists, nurses and
other health care professionals whose focus is central nervous
system tumors in children and adults. This year’s Annual
Scientific Meeting will be held November 15 – 18, 2018 at the
Marriott Hotel in New Orleans, Louisiana.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development f oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. Our clinical stage drugs are Annamycin, an
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, and WP1066, an immuno-stimulating STAT3
inhibitor targeting brain tumors, pancreatic cancer and AML. We are
also engaged in preclinical development of additional drug
candidates, including additional STAT3 inhibitors and compounds
targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
WP1122 to show safety and efficacy in patients. Although Moleculin
Biotech believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission (“SEC”) and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024